Reflectance Confocal Microscopy and Skin Biopsy: Where Can RCM Change the Decision?

A 2026 prospective real-world study suggests that RCM can help spare some biopsies in clinically equivocal lesions. Its value lies in better triage, biopsy guidance, and follow-up—not replacing histopathology.

A lesion looks suspicious enough to worry about, but not suspicious enough to make the next step obvious.

Dermoscopy helps. The uncertainty remains.

This is the diagnostic gray zone where reflectance confocal microscopy (RCM) becomes most useful.

For lesions that remain equivocal after clinical examination and dermoscopy, RCM provides real-time, noninvasive skin imaging of the epidermis and superficial dermis and can add another layer of information before a skin biopsy is performed.

The clinical boundary is clear:

RCM can influence whether, when, or where a biopsy is performed. It does not replace histopathology when tissue diagnosis is required.

A prospective real-world study published in the Journal of the American Academy of Dermatology in 2026 included 1,285 clinically equivocal lesions and reported that 58.6% of biopsies were potentially avoided after RCM assessment. The study also reported 70% concordance between RCM and histopathology for specific diagnoses.

Those numbers are compelling.

They also need context.

The Important Word Is “Equivocal”

The 2026 study did not look at every lesion seen in routine dermatology.

It focused on lesions that remained uncertain and had already been selected for RCM.

That is important because RCM for equivocal skin lesions is very different from using RCM as a universal screening tool.

A clearly malignant lesion may already warrant biopsy. A clearly benign lesion may not require another imaging step.

The more difficult cases sit between those two ends of the spectrum:

• pigmented lesions with conflicting clinical and dermoscopic features;

• facial lesions on chronically sun-damaged skin;

• lesions in cosmetically sensitive areas;

• large or heterogeneous lesions where the biopsy site itself is uncertain.

This is where RCM before skin biopsy can add useful information without pretending to replace tissue diagnosis.

What the 2026 Real-World Study Actually Found

The prospective single-center study evaluated 1,285 clinically equivocal lesions.

The main findings included:

• 58.6% of biopsies potentially avoided;

• 70% RCM–histopathology concordance for specific diagnoses;

• stronger concordance in head and neck lesions;

• better performance in nonpigmented and nonmelanocytic lesions, particularly basal cell carcinoma;

• an 88.2% potential biopsy-saving rate in the pediatric subgroup.

The pediatric figure is promising, but the subgroup was small.

The study also came from one experienced center, and not every lesion had histopathologic confirmation.

So the finding should not be turned into:

“RCM eliminates 58.6% of skin biopsies.”

A more accurate reading is:

In selected clinically equivocal lesions, RCM may help clinicians avoid some immediate biopsies while supporting structured follow-up.

That distinction is central to understanding whether RCM can reduce skin biopsies in real-world dermatology.

Where RCM Can Change the Biopsy Decision

RCM does not have only one useful outcome.

A reassuring RCM finding

Clinical examination and dermoscopy remain uncertain, but RCM shows features supporting a benign interpretation.

In an appropriate patient, the dermatologist may choose structured clinical and dermoscopic follow-up rather than immediate biopsy.

A suspicious RCM finding

A borderline lesion may show concerning cellular or architectural features on RCM.

In that situation, RCM has not avoided a biopsy.

It has strengthened the reason to perform one.

The lesion needs biopsy—but where?

Large or heterogeneous lesions can create a sampling problem.

A small biopsy may miss the most suspicious area.

RCM biopsy guidance can help identify regions that deserve closer sampling, making the technology useful even when histopathology is still required.

That is an important point: avoiding biopsy is only one possible benefit of RCM.

The Strongest Workflow Is Layered

Reflectance confocal microscopy works best as part of a diagnostic sequence:

clinical examination → dermoscopy → RCM for selected equivocal lesions → biopsy, treatment, or structured follow-up

A 2026 prospective multicenter study evaluated 2,006 equivocal flat head and neck macules from 801 patients using clinical assessment, dermoscopy, and RCM.

The study found that integrating RCM improved detection of lentigo maligna/lentigo maligna melanoma and improved specificity for benign lesions compared with dermoscopy alone, while a small residual risk of missed malignancy remained.

This supports RCM as an additional triage layer rather than a replacement for dermoscopy or histopathology.

For RCM dermatology workflows, that layered model is more realistic than placing every suspicious lesion directly into a confocal microscope.

RCM Still Has Limits

Reflectance confocal microscopy is noninvasive, but it cannot answer every diagnostic question.

Important limitations include:

• restricted imaging depth;

• operator-dependent image acquisition;

• a learning curve for interpretation;

• difficulty with some complex or deeper lesions;

• possible false-negative findings.

A reassuring RCM examination does not automatically end surveillance.

Patients whose biopsy is deferred may still need structured clinical and dermoscopic follow-up.

This is why the question “Can reflectance confocal microscopy replace biopsy?” has a straightforward answer:

No.

RCM can refine a biopsy decision. Histopathology remains the reference standard when tissue diagnosis is required.

Biopsy Avoidance Is Only One Part of the Value

The phrase “biopsy saving” gets attention because it is easy to quantify.

In practice, RCM may add value even when biopsy remains necessary.

It can help preserve tissue in selected lesions, support biopsy-site selection, provide immediate optical information during the visit, and allow the same area to be imaged again during follow-up.

These benefits are particularly relevant on cosmetically sensitive sites such as the face.

The 2026 multicenter head and neck study reinforces this point: RCM was used within a noninvasive triage pathway for difficult lesions rather than simply as a tool for avoiding procedures.

Expertise Is Part of the Technology

An RCM system is not a push-button diagnostic device.

The scanner matters, but so do:

• image acquisition;

• operator training;

• interpretation experience;

• case selection;

• follow-up protocols.

For hospitals, this changes the investment discussion.

Buying the imaging platform is only one part of building an RCM service.

A workable program also needs defined referral criteria, trained users, structured documentation, and a clear pathway for lesions that remain uncertain after imaging.

This is especially important when evaluating noninvasive skin imaging equipment for routine dermatology rather than research use.

Before Buying an RCM System, Ask Four Questions

Which lesions will actually be referred for RCM?

A defined population—such as lesions that remain equivocal after dermoscopy—is more useful than trying to scan every suspicious lesion.

Who will acquire and interpret the images?

Image quality and interpretation both depend on training.

What happens after a reassuring result?

If biopsy is deferred, the follow-up pathway must already be clear.

A negative RCM image should not allow a clinically relevant lesion to disappear from surveillance.

Can the system support real lesion navigation?

Resolution matters, but it is not enough.

Imaging depth, scanning field, image stitching, documentation, and repeat imaging also determine how practical the system will be for larger or heterogeneous lesions.

Where the KernelMed RCM-9503 Fits

The KernelMed RCM-9503 is an in vivo reflectance confocal microscopy platform designed for real-time, noninvasive dermatologic imaging.

Its current official product page identifies the system as the Reflectance Confocal Microscopy (RCM) System RCM-9503.

Key specifications include:

• 830 nm laser wavelength;

• optical lateral resolution <1.25 μm;

• optical axial resolution <5.0 μm;

• imaging depth ≥300 μm;

• scanning field of view 500 × 500 μm;

• image stitching up to 8.5 × 8.5 mm.

These parameters matter because RCM is not simply about magnification.

Resolution supports visualization of cellular and architectural detail. Imaging depth defines how far into superficial skin structures the system can examine. Image stitching helps clinicians navigate an area larger than a single microscopic field.

The hardware itself does not decide whether a lesion should be biopsied.

That decision remains clinical and is built from:

history + examination + dermoscopy + RCM findings + follow-up or histopathology

For hospitals and distributors evaluating an RCM system, the more useful question is whether the platform can support the acquisition quality, navigation, documentation, and repeatability required by trained dermatology teams.

So, Can RCM Reduce Skin Biopsies?

Current evidence supports a qualified yes.

In selected clinically equivocal lesions, real-world studies suggest that RCM can help reduce some immediate biopsies and improve biopsy targeting.

But the stronger conclusion is more precise:

RCM can refine whether, when, and where a biopsy is performed. Histopathology remains the reference standard when tissue diagnosis is required.

That is where reflectance confocal microscopy adds the most value—not as a shortcut around pathology, but as another layer of evidence before the clinician makes the next decision.

FAQ

Can RCM reduce unnecessary skin biopsies?

Yes, in selected patients. A 2026 prospective real-world study of 1,285 clinically equivocal lesions reported that 58.6% of biopsies were potentially avoided after RCM assessment. This result should not be generalized to all dermatology patients.

Can reflectance confocal microscopy replace biopsy?

No. RCM provides noninvasive optical imaging that can support biopsy decisions, but histopathology remains the reference standard when tissue diagnosis is required.

When should RCM be used before a skin biopsy?

RCM is most useful when a lesion remains equivocal after clinical and dermoscopic assessment, particularly when immediate biopsy is uncertain, the site is cosmetically sensitive, or better biopsy targeting is needed.

What is RCM biopsy guidance?

RCM biopsy guidance uses confocal imaging to help identify suspicious areas within a larger or heterogeneous lesion so that tissue sampling can be directed toward a more informative site.

What are the main limitations of RCM?

Important limitations include restricted imaging depth, operator dependence, training requirements, interpretation difficulty, and the possibility of false-negative findings.

What should clinics evaluate when purchasing an RCM system?

Beyond resolution, clinics should assess imaging depth, scanning field, image stitching, acquisition workflow, documentation, training, interpretation, technical support, and how RCM will fit into the existing clinical–dermoscopic–histopathologic pathway.

References

1. González-Valdés S, et al. Reflectance confocal microscopy reduces biopsies in adults and children: A prospective real-life study. Journal of the American Academy of Dermatology. 2026;94(1):120–127.
   PubMed record

2. Guida S, et al. Clinical and Dermoscopic Triage of Head and Neck Macules: The Role of Reflectance Confocal Microscopy in a Prospective Study of 2006 Lesions. Journal of the American Academy of Dermatology. 2026.
   PubMed record

3. Jain M, et al. Reflectance confocal microscopy: Principles, basic terminology, clinical indications, limitations, and practical considerations. Journal of the American Academy of Dermatology. 2021.

4. Ho G, et al. International expert recommendations on image acquisition for in vivo reflectance confocal microscopy of cutaneous tumors. Journal of the American Academy of Dermatology. 2024.

5. KernelMed. Reflectance Confocal Microscopy (RCM) System RCM-9503.
   KernelMed RCM-9503 product page